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Cancer therapy has evolved throughout the decades and is
beginning to branch off into new and exciting fields including
immunotherapy. The hope of this new field stems from the
lack of success of chemotherapy in general. Chemotherapy's
cytotoxic characteristics were regarded as one of three major
methods of treating cancer. The other two methods include
surgery and radiation. Due to a vast misunderstanding of the
role of chemotherapy in late stage cancer, the likelihood of a
full recovery from terminal cancer is close to zero [1]. Ad-
vances in genomics to aid in electing effective chemothera-
peutic agents increased the success rate of cancer treatments,
particularly when cancer has become metastatic [2]. Bio-
markers are molecular characteristics of biological functions
that can be readily measured or detected to determine cellular* Corresponding author. Envita Medical Center, 8759 E. Bell Road,
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research and treatment utilize this information to inform
physicians and researchers of targets for chemotherapy in
particular and can even be used to measure the effectiveness of
treatments in some circumstances.
These genomics-based tests are predominantly centered on
cancer biomarkers which have been used to further distinguish
cancer cells and aid in the understanding of how the cells
become cancerous. Some of these biomarkers are membrane
bound proteins that serve various functions in cancer cells and
even normal cells. However, these biomarkers from
membrane-bound proteins are typically unique or over
expressed. These kind of membrane-bound proteins that serve
as cancer biomarkers can be carefully leveraged in immuno-
therapy. Membrane-bound antigenic proteins can be distin-
guished further as either being tumor associated antigen
(TAA) and tumor specific antigens (TSA). TAAs are antigens
that are over expressed in some cancers and can be found in
other cells. TSA are antigens only found on cancers.
Many forms of immunotherapy have been proposed over
the years. These immunotherapies range from checkpoint
therapy [3], cancer vaccines [4], and oncolytic viruses [5].h Institute. Publishing services by Elsevier B.V. This is an open access article
.0/).
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pathways associated with the immune system or involve some
method of aiding antigen recognition. Oncolytic viruses infect
and replicate in only cancer cells or involve some form of gene
therapy through insertion of genes detrimental to cancer
survival.
Immunotherapy is relatively new compared to the three
primary pillars of cancer treatment: surgery, chemotherapy,
and radiation. Significant leaps in molecular biology tech-
niques, in particular, have advanced the understanding on how
the immune system works, in addition to how it can be
modulated. This has lead the scientific community to identify
the chimeric antigen receptor (CAR) as a potential target for
molecular genetics to insert new epitopes on the receptor re-
gion, allowing a degree of control of the immune system. This
paper will focus specifically on CAR T-cell therapy as an
immunotherapy.
This method involves reconstruction of the CAR receptor
found on T cells to recognize specific antigens on cells that are
to be destroyed. In principle and practice, this can include
ex vivo growth of T cells before they are genetically modified
by typically a retrotransposon introduced to the T cells by the
various methods including viral vectors [6].
There are three primary components of CAR receptor
including the extracellular domain, transmembrane, and
intracellular domain. The primary feature of the extracellular
domain is the scFv region which is similar to the light chain
region of an antibody. The transmembrane domain connects
the scFv region costimulatory molecules and can influence the
immunogenicity depending on its length. There are four kinds
of CAR T cell therapies that will be discussed. They involve
the absence or presence of costimulatory molecules or the
ability to stimulate cytokine production [7]. CAR T cell
therapies are separated by generation as the field has pro-
gressed. Although the second generation of CAR T cell ther-
apy has been resolved to have better cancer-killing potential
than the first, there is still ambiguity on how second-
generation CAR T cell therapy compared to the third or
fourth generation [7]. The fourth generation is significantly
different in its function of releasing cytokines and is also
known as T cell redirected universal cytokine killing
(TRUCK) [8].
This paper will discuss the role of the immune system
without immunotherapy to combat cancer and review the
various forms of CAR T cell therapy. This literature review
will also present a number of biomarkers used in CAR T cell
therapy in addition to discussing adverse events and ways to
mitigate such events.1.1. The immune systemImmune response can take two forms which include the
innate immunity and the adaptive immunity. Innate immunity
has the capability of recognizing foreign antigens without
harming self-cells and tissue. Recognition of foreign antigens,
like pathogen-associated immunostimulants, induce a response
of inflammation and phagocytosis involving innate immunecells like neutrophils and macrophage. Such a response occurs
quickly, even if the foreign pathogen-associated immunosti-
mulants have never been introduced to the body before. Much
of the recognition of bacteria cells, in particular, involve the
recognition of formylmethionine at the N-terminus since this
type of post-translational modification is absent in eukaryotes.
Other targets include, but are not limited to, peptidoglycan on
the flagella and cellular walls, teichoic acid on Gram-positive
bacteria, and lipopolysaccharides (LPS) on Gram-negative
bacteria. Common pathogen-associated immunostimulants
found on fungi include chitin, glucan, and zymosan.
Adaptive immunity takes more time to mount its response.
The thymus is largest during the first year of life, and it is
where T cells develop [9,10]. Neonatal T-cells reflect non-
inherited maternal alloantigens since they likely have not
been exposed to pathogen-associated immunostimulation.
Tolerogenic reactivity becomes a hallmark of the earliest T
cell immunity in early life. At the same time reduced alloan-
tigen recognition begins to occur yet there is still a very weak
response to foreign antigens. The multi-histocompatibility
complex (MHC) and its association of recognizing peptide
antigens are prominent in newborn children. However, the
adaptive immunity is still immature at this point of human
development. Exposure to various antigens to improve im-
mune function and aid the process of adaptive immunity.1.2. Immunologic interaction with cancerAmongst the adaptive immunity that is gained throughout
human development, the ability for T-cells to recognize
pathogen-associated immunostimulants by the topography of
foreign antigen's epitope is a critical component of adaptive
immunity. Adaptive immunity against various cancer forma-
tions often involves the use of T cells. This process is known
cancer immunoediting and involves three phases; elimination,
equilibrium, and escape. Although T cells are not exclusively
involved in the elimination, particularly during the process of
immune surveillance, for the sake of brevity, this section will
focus on the contribution of T cells and to the events leading
up to greater T cell involvement.
During elimination, foreign epitopes produced by cancer
cells induce an immune response where T cells eliminate
cancer cells. This is consistent with the theory of immune
surveillance where the immune system actively seeks out
cancer cells and eliminates them [11]. As tumors grow, they
enact mechanisms associated with angiogenesis in addition to
creating local inflammation surrounding the tumor site [12].
Inflammation coupled with the access provided by angiogen-
esis recruits a robust immune response including involvement
of NKT, NK, gd T cells, macrophages, and dendritic cells
where NKT, NK, and gd T cells produce IFN-g [13e15]. IFN-
g creates a direct and indirect mechanisms that lead to cell
death and subsequently the formation of cellular debris which
is shuttled to the lymph nodes. In the lymph nodes, dendritic
cells indirectly activate tumor suppressive CD8 [16e19] T
cells in an event that eventually leads to CD4 and CD8 T cells
to migrate to the tumor site to kill cancer cells [20].
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the same rate as cancer cellular growth. The remaining cancer
cells that survive the elimination phase begin to propagate in a
manner that creates a dynamic equilibrium associated with
tumor growth and immune response. If tumor cells are given
enough time to mutate and shift the equilibrium through sur-
vival consistent with Darwinian evolution, then those malig-
nant cells that have adapted against the immune response have
an opportunity to propagate unchecked respectively [11].
Therefore, escape occurs when cancer cells become unrec-
ognizable to the immune surveillance by means of mutation in
the genes or by the influence of epigenetic factors [11]. Further
inhibition of the immune surveillance by the formation of a
tumor microenvironment will also occur, thus inhibiting the
immune system's ability to conduct immune editing.
The mutations on the cellular membrane that are not
recognized by the immune system are of particular interest to
the field of immunotherapy. It is important to understand that
recognition by lymphocytes occurs in a spectrum where an-
tigens can be weakly immunogenic. This point is to clear the
air of an oversimplified binary recognition and evasion
perspective. Escape can also occur by tumors suppressing
recognizable antigens by downregulating their expression.1.3. ImmunotherapyImmunotherapy takes many forms in the treatment of
cancer. These include cancer vaccines, genetically modified
dendritic cells, stem cell immunotherapy, tumor infiltrating
lymphocytic immunotherapy, natural killer cell immuno-
therapy, natural killer T cell immunotherapy, cytokine-induced
killer cell immunotherapy, monoclonal antibody immuno-
therapy, peptide vaccines, exosomes, gold nanoparticle vac-
cines, IL-27, etc. [21].
Genetically modified dendritic cells aid in recognition and
subsequent immune action in the immunological cancer
response involving the relay of information via signaling to T
cells and B cells. Modified dendritic cells form a complex with
T cells to relay information involving antigen response which
can be influenced by co-stimulatory molecules as well as an-
tigen peptides on the dendritic cells to aid in self non-self
recognition. Co-stimulation of effect T cells by inhibiting
the induction of programmed cell death via apoptosis in
addition to inhibiting anergy or exhaustion.
Another form of cellular immunotherapy mentioned is
natural killer cell immunotherapy. Natural killer cells are also
known as CD56þ and CD3þ and have cytotoxic effects on
cancer cells. NK cell recognition of non-self elimination is
dependent on licensing by the KIR receptor before cytotoxic
effects against tumor cells can be activated [22e24]. Although
autologous NK transfer has been found to be ineffective
despite co-stimulation by IL-2 [25e27], promising initial re-
sults involving allogenic NK transfusion makes NK cell
immunotherapy attractive, particularly since low aberrant
cytotoxicity has been elucidated [28].
These previous immunotherapies vary in effectiveness in
the treatment of cancer. However, genetically modified T-cellsto express a modified chimeric antigen receptor (CAR) have
had significant success over the past few years, particularly in
treating leukemia and lymphoma cells expressing CD19
antigens.
2. CAR T cell therapy
The composition of the CAR involved in CAR T cell
therapy depends on the target and the generation of the CAR T
cell. The targets are typically surface antigens whose epitope
is unique to the cancer cells. It is important that the targets are
unique to the cancer to avoid various, and often unexpected,
consequences associated with autoimmune disease. The fre-
quency of novel CAR target surface antigens has yet to be
elucidated since there is potential for new novel CAR targets
that have not been discovered yet. In the case of the cancer
biomarker CD19, CD19 has an epitope that is not recognized
by immune cells respectively.
However, CAR T cells have been modified to recognize the
epitope and have had significant success in killing cancer cells
with such over expression. Although CD19 is commonly
found in lymphocytes, CD19 expression is a hallmark of
malignant B cells and is a target CAR T cells in chronic
lymphocytic leukemia (CLL) and acute lymphoblastic leuke-
mia (ALL) in addition to other various indolent lymphomas.
CD19 is not readily recognized by CAR T cells since it is a
self-antigen. However, depletion of lymphocyte via lympho-
cytopenia makes the opportunity for CAR T cells that recog-
nize CD19 on health lymphocytes virtually impossible. Under
these conditions, complications of off-target recognition can
be mitigated and repression of the T cells commonly found in
the tumor microenvironment found in solid cancers can be
ignored. Consequences and treatment associated with off-
target recognition of CAR T cell therapy will be explained
in detail in subsequent sections. Furthermore, targeting CD19
in over expressed CLL and ALL cells may improve the like-
lihood of detecting CD19 and could potentially increase the
rate of cancer elimination. Since the initial publications of first
generation T cells, there have been a variety of other surface
antigens that have been identified as targets for CAR T cell
immunotherapy. All of these modified CAR T cells have at
least modifications in the ectodomain. However, second and
third generations of CAR T cells contain further modifications
in the endodomain, involving the addition of costimulatory
molecules.2.1. Genetically modifying T cellsThere are various methods used to transfect CAR T cells
ex-vivo. These methods can include the use of viral vectors or
other methods to introduce the DNA or RNA. The insertion of
genetic material into the T-cells has also involved some form
of transposon/transposase system. Electroporation has also
been used to insert DNA or RNA vectors into T cells. Some of
the viruses commonly used for the development of modified T
cells often involve the use of a g-retrovirus or lentiviral vector
constructs.
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50% for optimized protocols with retroviruses ranging from
50% to 80% overall efficiency [29]. Lentiviral vectors have
been known to have greater efficiency with regard to infection
and replication due to their ability to grow in replicating and
quiescent cell lines [30]. In ongoing clinical trials, lentiviral
constructs account for 16 of the vectors and retroviruses ac-
count for 38 of the vectors used [31].
Lentiviral constructs differ from other retroviruses by their
ability to use the CD4 protein as a receptor. They are among
the most efficient methods of gene delivery as they have the
ability to utilize genome integration, the ability to infect both
dividing and non-dividing cells, and the capability of inserting
approximately 2.5e5.0 kb of genetic material. There are sig-
nificant differences in the biology of adenoviruses and lenti-
viruses. This includes adenovirus' double-stranded DNA
genome and their inability to integrate into the genome of
targeted cells. Adenoviruses are known for higher levels of
protein expression, the ability to infect dividing and non-
dividing cells, and have a greater range of genetic material
that can be transferred through viral vector; approximately
3.0e8.0 kb.2.2. T cell types and their involvement in CAR T cell
therapySeveral different kinds of T cells have been engineered to
express modified CARs. More specifically, engineered CD8þ
and CD4þ T-cell subsets have been found to have superior
anticancer properties in vivo studies [32]. CAR T-cell therapy
is at its best when T-cells can proliferate to a greater extent
in vivo and survive longer [33e38]. The key reason for these
T-cell subsets to have superior anticancer properties relies on
these principles and in turn have greater efficacy than if they
do not influence proliferation or are subject to more indis-
criminate transfection. To further complicate the issue, CD8þ
and CD4þ T-cells occur as memory (Tm), effector (Te), and
naïve (Tn) depending on the delineation associated with an-
tigen exposure as it affects the phenotype expressed as a
surface antigen. Memory CD8þ and CD4þ are further sub-
divided due to differences in self-renewal capacity, transcrip-
tion profile, and phenotypic characteristics. They are known as
either the shorter lived effector memory T-cells (Tem) or the
longer lived central memory T cells (Tcm).
Although autologous CAR T cell therapy typically does not
go as far as differentiating the groups and subgroups of T-cells
in all experiments, it is important to recognize that there are
unique constituents that undergo genetic engineering. Differ-
ences among patients, particularly in their disease state and
exposure to chemotherapy will have differing profiles of
various kinds of T cells and the extent that these T cells remain
in circulation. The efficacy of autologous CAR T cell immu-
notherapy can differ among patients in experiments that do not
undergo cellular differentiation, particularly when considering
the original T cells have a genetic variance between patient's
own T cells. Lymphocytopenia is encouraged in some treat-
ments involving CAR T cell immunotherapy, particularlywhen treating lymphoma and leukemia. Since lymphocyto-
penia has the potential to influence the profile, viability, and
efficacy of CAR T-cell immunotherapy, if these conditions
occur before the leukocytes are harvested, patients should be
monitored on an individual basis.
However, profiles of the kinds of T cells most prevalent in
patients with either full or partial response have begun to
emerge. Greater titers of CD8 have been shown to be a part of
the profiles of successfully treated patients with CAR T cell
therapy [39]. However, other reports indicate that higher titers
of CD4 TN and TCM subtypes and CD8 TN were indicative of
successful CAR T cell therapy in vivo [32]. Since the T cell
profile of an individual has not been resolved and because in-
dependent experiments often use different metrics to analyze
how the immune system is engaging in CAR T cell therapy in
general, there have been calls to have a more uniform manner
in the accumulation of data. For example, Klaver et al. suggest
that there should be a minimum amount of immunologic testing
throughout CAR T-cell administration congruent to the Inter-
national Society for Biological Therapy of Cancer Society for
Immunotherapy of Cancer, US FDA, and NCI Taskforce for the
development of biomarkers in immune therapy trials [39,40].2.3. Composition CARs in CAR T cell therapyThe CAR is of particular interest for immunotherapy since
the CAR can lead to T-cell activation via a mechanism that
involves antibody-like recognition [41]. The composition of
the CAR's epitope recognizing and binding region on the outer
surface of the T-cell is composed similarly to that of an
antibody [42]. The surface aspect of the receptor is bound to a
transmembrane domain that anchors the receptor and connects
to the intracellular domain which functions as a method to
impose both effector and trafficking in a persistent manner
[Fig. 1]. The intracellular domain is comprised of CD3-zeta
chain and is often incorporated with costimulatory molecules
that include CD27, CD28, CD134, and CD137. These cos-
timulatory molecules aid in signaling which in turn influences
the proliferation and the persistence of the T cell respectively
[38]. The first generation of CAR T cell therapy describes the
modification of the surface protein without the addition of
costimulatory molecules. The second generation describes
modifications on the surface of the CAR and the inclusion of
one costimulatory molecule. The first costimulatory molecule
used in second generation CAR T cell design was CD28. This
may explain in part CD28 popularity. CD28 costimulatory
molecule allowed for repeated antigen stimulation as well as
promoting proliferation. The effects of CD27 as a cos-
timulatory molecule that induces T cell proliferation is known,
however, there has been some speculation that CD27 is also
involved in T cell memory formation. CD134 and CD137
are similar to the extent that they are both costimulatory
molecules, but also since they are both members of the (Tumor
Necrosis Factor) TNF receptor family. CD70, CD80, CD86,
and CD137 have been shown to enhance the proliferation of T
cells in addition to the secretion of cytokines once stimulated
by antigen recognition [43] CAR The third generation is
Fig. 1. The four generations of CAR T cells are depicted in a manner that emphasizes the differences in the intracellular domain region of the CAR. It should be
noted that OX-40 is also known as CD134 and that 4-1BB is CD137 for the third generation. Two copies of the same costimulatory molecules are not used in third
generation CAR T cell design. Each generation increases in complexity concerning the addition of costimulatory molecules or NFAT induced promoter for IL-12
transcription and later translation.
Table 1
The following biomarkers have been used in various phases of
experimentation with different levels of success, efficacy, and
safety. The majority of the biomarkers are not completely unique
to the cancer itself. This in principle creates challenges in safety
particularly for autoimmune disease.
Biomarker Citation
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taining two costimulatory molecules instead of one. The fourth
generation, which can be referred to T cell redirected for
universal cytokine killing (TRUCK), can utilize nuclear factor
of activated T cell (NFAT) to induce a promoter associated
with a cassette containing IL-12 genes [8]. Although there has
been clear evidence that the second-generation of CAR T cell
therapy works better than the first generation [44], the efficacy
of third and fourth generation of CAR T cell design has not
been thoroughly resolved at this time.CD22 [54]
CD30 [55]



















VEGFR [96e99]The limitation of CAR T cell therapy is that targets cannot
be internal or present in other human cells respectively. The
epitope of the antigen needs to be unique enough for the scFv
region to recognize it without creating conditions associated
with autoimmunity. These unique antigens associated with the
cancer can be thought of as biomarkers. It is important to
recognize that the scFv region is not necessarily dedicated to
one specific type of antigen since recognition varies with re-
gard to immunogenicity to any given target. Traditionally, the
most promising biomarkers in cancer therapy involved muta-
tions that affected molecular pathways that either acted to
reduce tumor suppression or activate oncogenesis. However,
the search for novel external biomarkers that can be recog-
nized by CAR T cell therapy or some other form of immu-
notherapy has gained traction. With these restrictions in mind,
there has been a multitude of CAR T cell therapies that have
been proposed [Table 1]. The extent of the research and
desirable clinical outcomes differs for a variety of reasons. The
clinical outcomes likely differ due to the generation of CAR T
cell therapy, the kinds of T cells transfected in higher con-
centrations, the phenotypic expression of surface antigens in
healthy and cancerous cells, the kind of costimulatory mole-
cules used in the design of the CAR T cell therapy, the
specificity of the CAR recognition, and the occurrence of
autoimmunity, and cytokine release syndrome (CRS).
Balancing these qualities has been challenging and precisestrategies to maximize the potential of CAR T cell therapy and
to mitigate the side effects and toxicities is still respectively
unclear.2.5. Side effects and toxicity of CAR T cell therapyFinding a cancer treatment with little to no toxicity is rare.
Although the autologous nature of CAR T cell therapy at first
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CAR T cell therapy can have serious adverse events and
varying levels of toxicity respectively. A common problem
experienced particularly in successful CAR T cell therapy
might include CRS which can seriously harm or endanger a
patient [100]. The effects of CRS may include, hypotension,
hypoxia, high-grade fever, and neurological disturbance.
There are several ways to mitigate some of these adverse
events associated with CAR T cell therapy. These methods
include, but are not limited to, inhibiting the effect of cyto-
kines or by reducing the amount of cytokines via indirect
method [32]. Tocilizumab works by blocking cytokines at the
receptor which alleviates issues with CRS but should be
avoided if macrophage activation syndrome (MAS) is sus-
pected [32]. Corticosteroids on the other hand indirectly
reduce cytokine levels through the reduction of transduced T
cells that are respectively causing the CRS and can also be
used to reduce inflammation and graft versus host disease [32].
Methotrexate may also have a beneficial indirect mode of
action in addition to treating complications associated with an
autoimmune disease that can be caused by off-target CAR T
cells.
The treatment of autoimmune disease is complicated by the
loci of the mistargeted tissue and the extent of the damage in
that region in general. There recently has been a novel method
introduced to prevent or mitigate the effects of autoimmune,
inflammatory, and allograft targeted immune response by way
of genetically modified T-reg cells. Without genetic modifi-
cations, CD4þ CD25þ Tregs by adoptive transfer has the
capability of reducing autoimmune disease in some circum-
stances. Polyclonal Tregs do not have the same capacity to
limit pathogenic immune response when compared to Tregs
that have proper specificity to antigens associated with either
the diseased or allograft organs [101e103]. The practice in
itself is in its infancy but does suggest that modifications of the
immune system to safely treat cancer may include more than
one type of T cell modification to balance potential adverse
events from CAR T cell therapy. After all, pretreatment to
mitigate adverse side effects is a standard practice in oncology
and should be considered with CAR T cell therapy.
3. Discussion
One of the issues facing CAR T cell therapy consistency
involves composition of T cells that are transduced to express
various CARs. Many chemotherapies are known to induce
lymphopenia in patients. This is predominantly due to the
toxic nature of the chemotherapies. What is unknown is how
each individual chemotherapy potentially depletes certain
types of lymphocytes more so than other lymphocytes. Per-
sonal characteristics associated with the patient's genome and
epigenome or recent exposure to a pathogen, in particular, are
likely to influence the counts of various lymphocytes too. To
further complicate this, patients are likely to go through
different phases of chemotherapy before being introduced to
immunotherapies such as CAR T cell therapy. These factors
create inconsistencies in the various T cells titers. As discussedearlier, higher concentrations of transformed CD4 and CD8
CAR T cell subsets were correlated to greater killing potential
[32]. As research and acceptance of immunotherapy increases
amongst oncologist, there is potential for enhancing the ben-
efits of CAR T cells by choosing to treat with immunotherapy
before administration of chemotherapeutics in order to control
for variability in lymphocytes. Methodology for isolating and
expanding titers of specific kinds of T cells before being
transduced should be implemented and examined to optimize
what might be considered specific T cell dosing.
The tumor microenvironment remains a significant hurdle
for CAR T cells to work efficiently. As discussed earlier, the
escape phase occurs when the cancer cell is unresponsive to
the immune system, evades the immune system, or creates a
tumor microenvironment that inhibits the immune system. The
tumor microenvironment is rarely addressed beyond stating
that it is a barrier to most immunotherapies. This could lead to
a market for a new drug or treatment that mitigates the effects
of the tumor microenvironment to enhance various immuno-
therapies and could even potentially be used prophylactically
to reduce the likelihood of the escape phase in cancer devel-
opment. Although TRUCKS aim to mitigate the tumor
microenvironment, the available research on the subject has
yet to produce enough data to support these ideas or if other
modifications are necessary to reach its set goal.
The influence of cytokines as an immune response is
powerful and potentially dangerous to patients particularly at
risk to CRS, which can be induced by many CAR T cell im-
munotherapies. The extent of which cytokines are released in
any given patient involved in CAR T cell immunotherapy is
hard to predict or even control. However, tests can be per-
formed at various points of CAR T cell therapy to present a
clearer picture of what kind of cytokines are produced, at what
concentration, and the progress of CAR T cell therapy. Such
information could lead to a better understanding of the influ-
ence that CAR T cell therapy has on an important facet of the
immune system. This may even reveal a pattern in statistics
that could inform the patient of the potential danger associated
with CRS.
Autoimmune disease is a very dangerous consequence of
CAR T cell therapy as well. Unlike with treatment of leukemia
using CD19 as a biomarker associated leukemia and lym-
phoma, it is difficult to eliminate potential healthy cellular
antigens that could inadvertently be targeted instead of the
cancer cells since induced lymphocytopenia is the primary
reason for CAR T cell therapy does not recognize self-
lymphocytes containing CD19.
Predictive methods for determining if there are similar
epitopes on antigens throughout the body needs to be devel-
oped to prevent treatments that could potentially put the pa-
tient at greater risk. Although prediction of such antigens by in
silico analysis using specifically tailored bioinformatics is far
from being a reality, there is potential to introduce tagged
antibodies or other forms of anti-sequence antigens to see if
the antigen recognizing molecules localize in regions not
associated with the tumor or its metastases. As long as these
antigen recognizing molecules do not bind to the tumor in an
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similar antigens that could accidently or less specifically be
recognized by CAR T cell therapy. As explained earlier, an-
tigen recognition is not binary, and CAR can be weakly
immunogenic to various epitopes in a manner that could cause
autoimmune disease. Therefore, the production of antigens
that loosely recognizes biomarkers, like tagged antibodies
with a weak association to the epitope of the antigen found on
the surface of the cancer but offer stronger and potentially
inhibitory binding of antigens on self-cells, could be utilized to
narrow the target of CAR T cells. If used in concentrations that
do saturate similar antigens that could accidentally be recog-
nized by CAR T cells, then, in theory, there is potential to
reduce the risk of autoimmune disease that can occur from
CAR T cell therapy. Other methods involving the modulation
of tolerogenic functions should be explored in conjunction
with immunotherapy to mitigate adverse events like an auto-
immune disease.
The use of genetically modified Treg cells was introduced
to show a novel method for controlling autoimmune disease.
This was also mentioned because, in order to optimize to a
theoretical mastery of immunotherapy, there must be total
control of the immune system to make it do exactly what the
physician would like it to do. In the case of treating leukemia
with anti-CD19 CAR T cell immunotherapy, the immune
system was completely depleted before the administration of
the genetically modified CAR T cells were introduced to the
patient. This was largely because CD19 is also present on
healthy immune cells. However, the consequence was a better
control of the immune system as a whole for a period of time.
Attaining a theoretical mastery of the immune system while
using CAR T cells would have to involve more than one
immunotherapy to control better for adverse events associated
with CAR T cell therapy and better monitoring and control of
other immunological events like cytokine release.
Immunotherapy as whole is complicated and, to an extent,
disjointed from various treatments. However, in the future,
more immunotherapies will begin to intersect and potentially
synergize efforts to enact whatever its purpose might be. As
scientists rush to find the latest biomarker that could be tar-
geted by a specific CAR T cell therapy using various gener-
ations, each will experience similar consequences as the CAR
T cell therapies before it without finding novel ways to prevent
adverse events. It is important to know whether a particular
biomarker would indeed be beneficial for cancer treatment. It
appears that many scientists are selecting what they believe to
be the most unique biomarker on the surface of a cancer cell
and hoping that the variable region of the CAR T cell does not
recognize something else, cause CRS, or some other problem.
Finding truly unique biomarkers on the surface of neoplastic
cells and then creating an scFv region to recognize and kill
that neoplastic cell is an ideal circumstance that is truly rare.
This is particularly true since there is potential for genetic drift
among humans. This could create an antigen with an epitope
similar to cancer that had previously been safely and effec-
tively treated by CAR T cell therapy. Although it is still a high
priority to find distinctly unique biomarkers on the surface ofneoplastic cells to be recognized by scFv, even the most ideal
forms of CAR T cell therapy should have greater protective
measures, novel genetic modifications on CAR T cell like
costimulatory molecules, potential pretreatment or prescreen-
ing of modified CAR recognition in self vs nonself, and ge-
netic screening for in silico analysis to determine the extent
the epitopes underlying genetics that are unique to the cancer.
This is particularly important for CAR T cell therapies that
have had unforeseen immunological events in the past. After
all, those treatments might end up being even more of a
specialized treatment than originally intended but still viable
under certain circumstances.
The problems associated with CAR T cell therapy might
not be solved just by augmenting scFv region and changing the
costimulatory molecules alone. Scientists may have to take a
step back and think of novel ways to make CAR T cells safer
and more efficient on solid tumors to significantly advance the
science.
4. Conclusion
The field of immunotherapy is still in its infancy. Many new
targets have been and will be introduced for CAR T cell
therapy. Despite the excitement, there are significant limita-
tions to the practice particularly due to adverse consequences
associated with autoimmune disease. Although the respec-
tively successful treatment of leukemia, the experimental pa-
rameters did not address the tumor microenvironment that can
inhibit lymphatic cells. Many of the scientists involved in
CAR T cell therapy are chasing the latest CAR T cell therapy
design for the most novel biomarker. However, it might be
time for a more serious evaluation of ways to gain a theoretical
mastery of the immune system which could potentially free
CAR T cell therapies from adverse events in the future.
Despite these potential setbacks, CAR T cell therapy has a
place as a promising form of immunotherapy and the potential
for significant improvements in patient outcomes, particularly
patients with cancer.
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